Abstract: A method for evaluating the rheological properties of at least one gel, consisting in determining the extent of the plastic domain in stress ?c??p, and in strain ?c??p, the determination being carried out according to the steps: subjecting at least one sample of at least one gel to oscillating mechanical stresses at a fixed frequency, determining and plotting curves of the elastic modulus G? and the viscous modulus G? as a function of the strain and stress, determining ?c and ?p at the point of intersection Xc of the curves of G? and G? under stress and strain, determining ?p and ?p by fixing an arbitrary value of G? (G?x) that is defined as the entry value into the plastic domain, and calculating ?c??p and ?c??p.

Abstract: A method for incorporating at least one organic compound within a hydrogel, wherein the incorporation is carried out by dialysis, the organic compound being solubilized in the dialysis solution at a concentration equal to or greater than the target concentration.

Abstract: A process for crosslinking a polymer, includes at least the following steps: a) providing a polymer; b) providing a crosslinking agent; c) carrying out one or more crosslinking steps in the presence of the polymer and the crosslinking agent; d) obtaining a crosslinked polymer; wherein the crosslinking step or each of the crosslinking steps is carried out at constant temperature or at a temperature that varies linearly or in a stepwise manner, the constant or variable temperature being less than or equal to 15° C., and in that the crosslinking step c) has a duration of between 3 and 72 hours.

Abstract: A syringe has a syringe body configured to receive a product for injection. Gripping wings are arranged at one end of the syringe body. A piston rod is mounted so as to be able to slide inside the syringe body. A stop is arranged at a first end of the piston rod and has an end-of-travel position inside the syringe body. A pusher is arranged at a second end of the piston rod. The pusher has a mass greater than or equal to a threshold value beyond which the syringe has a center of gravity situated outside the syringe body when the stop is in the end-of-travel position.

Abstract: A biodegradable single-phase cohesive hydrogel includes a homogenous mixture of 2 to 5 identical or different polymers interpenetrating each other in a single phase, wherein the polymers are independently crosslinked prior to interpenetration by mixing, and the crosslinked polymers are insoluble in water and miscible with each other.

Abstract: A sterilized aqueous composition includes at least one hyaluronic acid or salt thereof and at least mepivacaine or salt thereof. The weight ratio between the concentration of hyaluronic acid [HA] and the concentration of mepivacaine [MEPI]-[HA]/[MEPI]- is no lower than 0.1. Mepivacaine may be used as a substitute for lidocaine in an equivalent amount in order to obtain a hyaluronic acid composition including a local anaesthetic with rheological properties after heat sterilization that are superior to the rheological properties of the same composition of hyaluronic acid except including lidocaine.

Abstract: A biodegradable single-phase cohesive hydrogel includes a homogenous mixture of 2 to 5 identical or different polymers interpenetrating each other in a single phase, wherein the polymers are independently crosslinked prior to interpenetration by mixing, and the crosslinked polymers are insoluble in water and miscible with each other.

Abstract: A process of preparing a biodegradable single-phase cohesive hydrogel composition includes preparing 2 to 5 hydrogels that are independently crosslinked so that each hydrogel has a degree of crosslinking in a range from 0.02 to 0.4, and mixing the 2 to 5 hydrogels to obtain a homogenous mixture of 2 to 5 intertwined hydrogels that interpenetrate each other to form a single phase without covalent bonding between the hydrogels, wherein each hydrogel is prepared by a process that comprises independently crosslinking a polymer and the total polymer concentration of the composition is in a range from 5 to 50 mg/g.

Abstract: An injectable sterilized aqueous composition including at least one hyaluronic acid, at least one polyol and at least one local anesthetic chosen from the group made of benzocaine, chloroprocaine, procaine, etidocaine, aptocaine, chlorobutanol, diamocaine, dyclonine, guafecainol, polidocanol, mepivacaine, prilocaine, articaine, bupivacaine, ropivacaine, tetracaine and salts thereof and isolated isomers thereof. The invention also relates to a process for adapting the rheological properties of a heat sterilized injectable aqueous composition. The invention also relates to a process for producing an injectable sterilized aqueous composition according to the invention, and also to uses of said injectable sterilized aqueous composition according to the invention.

Abstract: The invention relates to a sterilized composition comprising at least one hyaluronic acid or biologically acceptable salt thereof, alone or in a mixture, and magnesium ascorbyl phosphate, in a ratio [HA]/[MAP] by mass of the amount of hyaluronic acid or salt thereof [HA] to the amount of magnesium ascorbyl phosphate [MAP] of greater than or equal to 1, the amount of magnesium ascorbyl phosphate being between 0.001% and 1% by weight, relative to the total weight of said composition, with an elastic component G? which is retained or improved after sterilization and is between 5 and 400 Pa. It also relates to a composition of the invention which further includes dimethyl sulfone, to methods for producing same, and to uses thereof.

Abstract: An injectable sterilized aqueous composition including at least one hyaluronic acid, at least one polyol and at least one local anesthetic chosen from the group made of benzocaine, chloroprocaine, procaine, etidocaine, aptocaine, chlorobutanol, diamocaine, dyclonine, guafecainol, polidocanol, mepivacaine, prilocaine, articaine, bupivacaine, ropivacaine, tetracaine and salts thereof and isolated isomers thereof. The invention also relates to a process for adapting the rheological properties of a heat sterilized injectable aqueous composition. The invention also relates to a process for producing an injectable sterilized aqueous composition according to the invention, and also to uses of said injectable sterilized aqueous composition according to the invention.

Abstract: Biodegradable single-phase cohesive hydrogels useful, e.g., for the formulation of viscosupplementation compositions or compositions for filling wrinkles, contain a homogeneous blend of x polymers, which may be identical or different, crosslinked prior to the interpenetration thereof by mixing in the form of a single-phase hydrogel, wherein such crosslinked polymers are insoluble in water and miscible with one another, and x ranges from 2 to 5; in one embodiment, the hydrogels are such that the x polymers have identical or different degrees of crosslinking, at least one of the x polymers having a degree of crosslinking x1 and at least one of the x polymers having a degree of crosslinking x2, with x1 being greater than or equal to x2.

Abstract: A process of preparing a biodegradable single-phase cohesive hydrogel composition includes preparing 2 to 5 hydrogels that are independently crosslinked so that each hydrogel has a degree of crosslinking in a range from 0.02 to 0.4, and mixing the 2 to 5 hydrogels to obtain a homogenous mixture of 2 to 5 intertwined hydrogels that interpenetrate each other to form a single phase without covalent bonding between the hydrogels, wherein each hydrogel is prepared by a process that comprises independently crosslinking a polymer and the total polymer concentration of the composition is in a range from 5 to 50 mg/g.

Abstract: A sterilized aqueous composition includes at least one hyaluronic acid or salt thereof and at least mepivacaine or salt thereof. The weight ratio between the concentration of hyaluronic acid [HA] and the concentration of mepivacaine [MEPI]—[HA]/[MEPI]—is no lower than 0.1. Mepivacaine may be used as a substitute for lidocaine in an equivalent amount in order to obtain a hyaluronic acid composition including a local anaesthetic with rheological properties after heat sterilization that are superior to the rheological properties of the same composition of hyaluronic acid except including lidocaine.

Abstract: The invention relates to a sterilized composition comprising at least one hyaluronic acid or biologically acceptable salt thereof, alone or in a mixture, and magnesium ascorbyl phosphate, in a ratio [HA]/[MAP] by mass of the amount of hyaluronic acid or salt thereof [HA] to the amount of magnesium ascorbyl phosphate [MAP] of greater than or equal to 1, the amount of magnesium ascorbyl phosphate being between 0.001% and 1% by weight, relative to the total weight of said composition, with an elastic component G? which is retained or improved after sterilization and is between 5 and 400 Pa. It also relates to a composition of the invention which further includes dimethyl sulfone, to methods for producing same, and to uses thereof.

Abstract: A composition including at least one crosslinked or non-crosslinked hyaluronic acid, or one of its salts, and at least one water-soluble salt of sucrose octasulphate, to processes for the manufacture of said composition and to the use of said composition for the formulation of a viscosupplementation composition or for the formulation of a composition as a dermal filler or for the formulation of a cosmetic composition.

Abstract: A process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups, in an aqueous phase, which includes the following steps: a polysaccharide is placed in an aqueous medium, it is brought into the presence of at least one precursor of a substituent, it is brought into the presence of a crosslinking agent, the substituted and crosslinked polysaccharide is obtained and isolated, wherein process is carried out in the presence of a basic or acidic catalyst, the concentration of which is between 3.16×10?7 and 0.32 mol/L, and at a temperature of less than 60° C. In one embodiment, the polysaccharide is in the form of a gel or hydrogel which is used in particular as augmentation biomaterial.

Abstract: A method of treating a vaginal or vulvar vestibule mucosa disorder involves administering a composition comprising a hyaluronic acid or a salt thereof to the vagina, vulvar or vulvar vestibule of an individual that has the disorder to treat the disorder. The method may be used to treat vaginal atrophy or vulvar vestibulitis syndrome, among other vulvovaginal mucosa disorders.